Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks.

The Journal of clinical investigation | 2013

The ability to map the functional connectivity of discrete cell types in the intact mammalian brain during behavior is crucial for advancing our understanding of brain function in normal and disease states. We combined designer receptor exclusively activated by designer drug (DREADD) technology and behavioral imaging with μPET and [18F]fluorodeoxyglucose (FDG) to generate whole-brain metabolic maps of cell-specific functional circuits during the awake, freely moving state. We have termed this approach DREADD-assisted metabolic mapping (DREAMM) and documented its ability in rats to map whole-brain functional anatomy. We applied this strategy to evaluating changes in the brain associated with inhibition of prodynorphin-expressing (Pdyn-expressing) and of proenkephalin-expressing (Penk-expressing) medium spiny neurons (MSNs) of the nucleus accumbens shell (NAcSh), which have been implicated in neuropsychiatric disorders. DREAMM revealed discrete behavioral manifestations and concurrent engagement of distinct corticolimbic networks associated with dysregulation of Pdyn and Penk in MSNs of the NAcSh. Furthermore, distinct neuronal networks were recruited in awake versus anesthetized conditions. These data demonstrate that DREAMM is a highly sensitive, molecular, high-resolution quantitative imaging approach.

Pubmed ID: 24231358 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

Associated grants

  • Agency: NIDA NIH HHS, United States
    Id: DA023214
  • Agency: NIDA NIH HHS, United States
    Id: DA007135
  • Agency: NIDA NIH HHS, United States
    Id: T32 DA007135
  • Agency: NIAAA NIH HHS, United States
    Id: AA11034
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA015446
  • Agency: NIDA NIH HHS, United States
    Id: DA030359
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA023214
  • Agency: NIDA NIH HHS, United States
    Id: DA015446
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA030807
  • Agency: NIAAA NIH HHS, United States
    Id: AA07574
  • Agency: NIAAA NIH HHS, United States
    Id: P50 AA007611
  • Agency: NIAAA NIH HHS, United States
    Id: R01 AA011034
  • Agency: NIAAA NIH HHS, United States
    Id: AA07611
  • Agency: NIAAA NIH HHS, United States
    Id: T32 AA007574
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA030359

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Methionine Enkephalin Antibody (antibody)

RRID:AB_572250

This polyclonal targets Methionine Enkephalin

View all literature mentions